Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: A single-center, randomized, controlled trial in Argentina

Cancer

Volumn 97, Issue 7, 2003, Pages 1775-1780

  Paganini, Hugo ^a,b   Gómez, Sandra ^a   Ruvinsky, Silvina ^a   Zubizarreta, Pedro ^a   Latella, Antonio ^a   Fraquelli, Lidia ^a   Iturres, Alejandro Santillán ^a   Casimir, Lidia ^a   Debbag, Roberto ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b NONE   (Argentina)

Author keywords

Child; Fever; Neutropenia; Oral therapy; Outpatient

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN;

ANTIBIOTIC THERAPY; ARGENTINA; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HOSPITAL DISCHARGE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; AMBULATORY CARE; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ARGENTINA; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; FEMALE; FEVER; HUMANS; INFANT; LEUKEMIA; MALE; NEUTROPENIA; RISK;

EID: 0037378474     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11251     Document Type: Article

References (26)

1. Hughes WT, Armstrong D, Bodey G, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
2. Baorto EP, Aquino V, Mullen CA, Buchanan GR, DeBaun MR. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer. 2001;92:909-913.
3. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol. 2001;19:3414-3421.
4. Talcott JA, Whalen A, Clark J, Rieker P, Finberg R. Home antibiotic therapy for cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107-114.
5. Rackoff W, Gonin R, Robinson C, Kreissman S, Breitfels P. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol. 1996;14:919-924.
6. Paganini H, Bologna R, Debbag R, et al. Fever and neutropenia in children with cancer in one pediatric hospital in Argentina. Pediatr Hematol Oncol. 1998;15:405-413.
7. Griffin TC, Buchanan GR. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early hospital discharge. J Pediatr. 1992;121:28-33.
8. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148:2561-2568.
9. Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer. 2000;88:1710-1714.
10. Paganini H, Rodriguez Brieshcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. A randomized controlled trial. Cancer. 2001;91:1563-1567.
11. Talcott JA. Outpatient management of febrile neutropenia. Int J Antimicrob Agents. 2000;16:169-171.
12. Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents. 2000;16:107-111.
13. Poretz DM, Eron JL, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA. 1982;248: 336-339.
14. Tice AD. Outpatient parenteral antibiotic therapy for fever and neutropenia. Infect Dis Clinics North Am. 1998;12:963-977.
15. Paganini H, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer. 2000;88:2848-2852.
16. Mullen CA, Petropuolos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126-134.
17. Madsen K, Rosenman M, Hui S, Breitfeld PP. Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia. J Pediatr Hematol Oncol. 2002;24:256-262.
18. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
19. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18: 3038-3051.
20. Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med. 1995;98:224-231.
21. Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. Oncology. 1996;10:599-606.
22. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305-311.
23. Shenep JL, Flynn PL, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis. 2001;32:36-43.
24. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993;71:3640-3646.
25. Kern WV, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999;341:312-318.
26. Shemsesh E, Yaniv I, Drucker M, et al. Home intravenous antibiotic treatment for febrile episodes in immune-compromised pediatric patients. Med Pediatr Oncol. 1998;30: 95-100.